Quantcast
Last updated on April 17, 2014 at 14:48 EDT

Latest News, Developments and Drug Pipelines for Central Nervous System Multiple Sclerosis

July 17, 2008

Research and Markets http://www.researchandmarkets.com/research/d8e5b4/central_nervous_sy) has announced the addition of the “Central Nervous System Multiple Sclerosis” report to their offering.

“Central Nervous System Multiple Sclerosis” contains detailed information on the current drug pipeline.

This report provides insight into the pipeline status of drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence.

Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development.

Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

— Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

— Keep track of your competitors and partners by better understanding their product pipeline.

— Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

— Maintain a critical competitive advantage.

Key Topics Covered:

RECENT HIGHLIGHTS AND CHANGES

— Recent Highlights and Changes

Multiple Sclerosis Pipeline Overview

— % of Projects (By Phase of Development)

— No. of Projects by Phase of Development

— Marketed Products Vs. Pipeline Products

Company Overview – Pipeline Projects

— Company Overview – Pipeline Projects

Top Companies in late stage Multiple Sclerosis Projects

— Active Biotech

— Abbott Laboratories

— Bayer HealthCare Pharmaceuticals

— Berlex, Inc.

— AutoImmune Inc

— BioMS Medical Corp.

— Biogen Idec Inc

— Centocor, Inc.

— BioPartners GmbH

— Eli Lilly & Co

— Elan Corp Plc

— Merck Serono S.A.

— Genentech Inc

— Novartis AG

— Millennium Pharmaceuticals Inc

— Pipex Pharmaceuticals, Inc.

— Pepgen Corporation

— Sanofi-Aventis

— Roche Holdings Ltd

— Teva Pharmaceutical Industries Ltd

— Teva Neuroscience

Top Companies in early stage Multiple Sclerosis Projects

— Aegera Therapeutics Inc.

— Acorda Therapeutics Inc

— Biogen Idec Inc

— AstraZeneca Plc

— BTG plc

— Bionomics Limited

— Genentech Inc

— ChemoCentryx, Inc.

— Medivir AB

— Hollis-Eden Pharmaceuticals Inc

— Merrimack Pharmaceuticals, Inc.

— Merck Serono S.A.

— Peptimmune, Inc

— MultiCell Technologies Inc

— Plexxikon Inc

— Pharmaxis Ltd.

— Tolerx, Inc.

— Teva Pharmaceutical Industries Ltd

— ZymoGenetics Inc

— Xencor

Pipeline Revenue

— Pipeline Revenue

Full Pipeline View

— Pre Clinical Pipeline View

— Phase I Pipeline View

— Phase II Pipeline View

— Phase III Pipeline View

— Pending Approval Pipeline View

— Post Marketing Pipeline View

— On the Market Pipeline View

— Discovery/Development Pipeline View

For more information visit http://www.researchandmarkets.com/research/d8e5b4/central_nervous_sy.

Source: Life Science Analytics